NanOlogy™ has transformed systemic chemotherapy into local delivery directly to the site of disease to improve the lives of patients with cancer and other serious illnesses.

nanoparticle production technology platform
Starting with the world’s most prescribed systemic chemotherapy agents, our patented submicron particle production technology platform uses sonic energy and supercritical carbon dioxide to reduce paclitaxel and docetaxel API crystals by up to 400 times into stable, naked particles with exponentially increased surface area and unique geometry. Our submicron particles are suspended prior to use in simple vehicles and locally administered in a concentrated form directly to the site of disease where they have been shown to release drug for weeks at a time.
A broad clinical trial program is underway in 2017 for NanoPac® (nanoparticle paclitaxel) including clinical trial evaluation of our sterile suspension in ovarian cancer (with orphan drug designation), prostate cancer, pancreatic cancer, pancreatic mucinous cysts, and clinical trial evaluation of our SOR007 ointment in cutaneous metastases and actinic keratosis under our affiliate, Soria. In addition, clinical trials are planned in 2018 for NanoDoce® (nanoparticle docetaxel) pending successful nonclinical development and approval of an investigational new drug application.  Finally, an inhaled version of NanoPac is under development for lung cancer.
transforming the delivery of proven drugs

(817) 900-4002
3909 Hulen Street
Fort Worth, Texas 76107